Congestive Heart Failure Hospitalizations and Cannabis Use Disorder (2010-2014): National Trends and Outcomes.
cannabis use disorder
congestive heart failure
length of stay
marijuana
mortality
trends
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
02 Jul 2020
02 Jul 2020
Historique:
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Prior studies have suggested that cannabis use is an independent risk factor for heart failure. With increasing recreational use of cannabis and decriminalization policies, cannabis use is expected to add to the burden of heart failure, but there is still limited data. Therefore, we utilized the Nationwide Inpatient Sample (NIS) database (2010-2014) to study the national trends and outcomes among cannabis users admitted for congestive heart failure (CHF). We queried the NIS database and identified CHF as the primary diagnosis with a co-diagnosis of cannabis use disorder (CUD). Trends were analyzed with the linear-by-linear association. Total CHF admissions (N = 4,596,024) with comorbid CUD (N = 23,358 (0.5%)) were identified. An increasing prevalence trend from 0.4% to 0.7% (P= 0.001) was seen. CUD patients had a mean age of 49.78 years, 79% were males, 55.4% were African Americans, and 73.6% earn ≤ 50th percentile median household income of the patient's ZIP code. Inpatient deaths (1.1% vs. 3.1%) were lower (P<0.001), and mean length of stay (LOS) was shorter among cannabis users compared to non-users (P=0.001). The mean LOS and total hospitalization costs demonstrated an increasing trend (P CUD was associated with reduced inpatient deaths, but the prevalence of CUD and hospital charges is on the rise in the CHF inpatient population in addition to shorter mean LOS. Notwithstanding, these above findings prompt further research into its underlying mechanisms along with a probable causal relationship between cannabis and heart failure.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Prior studies have suggested that cannabis use is an independent risk factor for heart failure. With increasing recreational use of cannabis and decriminalization policies, cannabis use is expected to add to the burden of heart failure, but there is still limited data. Therefore, we utilized the Nationwide Inpatient Sample (NIS) database (2010-2014) to study the national trends and outcomes among cannabis users admitted for congestive heart failure (CHF).
METHODS
METHODS
We queried the NIS database and identified CHF as the primary diagnosis with a co-diagnosis of cannabis use disorder (CUD). Trends were analyzed with the linear-by-linear association.
RESULTS
RESULTS
Total CHF admissions (N = 4,596,024) with comorbid CUD (N = 23,358 (0.5%)) were identified. An increasing prevalence trend from 0.4% to 0.7% (P= 0.001) was seen. CUD patients had a mean age of 49.78 years, 79% were males, 55.4% were African Americans, and 73.6% earn ≤ 50th percentile median household income of the patient's ZIP code. Inpatient deaths (1.1% vs. 3.1%) were lower (P<0.001), and mean length of stay (LOS) was shorter among cannabis users compared to non-users (P=0.001). The mean LOS and total hospitalization costs demonstrated an increasing trend (P
CONCLUSION
CONCLUSIONS
CUD was associated with reduced inpatient deaths, but the prevalence of CUD and hospital charges is on the rise in the CHF inpatient population in addition to shorter mean LOS. Notwithstanding, these above findings prompt further research into its underlying mechanisms along with a probable causal relationship between cannabis and heart failure.
Identifiants
pubmed: 32766001
doi: 10.7759/cureus.8958
pmc: PMC7398720
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e8958Informations de copyright
Copyright © 2020, Ajibawo et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Harm Reduct J. 2019 Jan 28;16(1):9
pubmed: 30691503
Nat Rev Cardiol. 2011 Jan;8(1):30-41
pubmed: 21060326
N Engl J Med. 2010 Apr 22;362(16):1453-7
pubmed: 20410512
Public Health Nutr. 2001 Jun;4(3):781-6
pubmed: 11415485
J Cardiovasc Med (Hagerstown). 2018 Sep;19(9):480-484
pubmed: 29879084
Circulation. 2004 Oct 5;110(14):1996-2002
pubmed: 15451779
J Cardiovasc Pharmacol. 2003 Apr;41(4):657-64
pubmed: 12658069
Am J Med. 2020 Feb;133(2):207-213.e1
pubmed: 31369724
Am J Med. 2017 Jun;130(6):678-687.e7
pubmed: 28161344
Circulation. 2011 Nov 29;124(22):e556-7
pubmed: 22125192
J Physiol. 2004 Jul 15;558(Pt 2):647-57
pubmed: 15121805
Drug Alcohol Depend. 2012 Jan 1;120(1-3):22-7
pubmed: 22099393
Curr Drug Saf. 2011 Nov 1;6(5):277-84
pubmed: 22424534
Addiction. 1998 Jun;93(6):837-46
pubmed: 9744119
Hawaii J Med Public Health. 2014 Apr;73(4):115-8
pubmed: 24765560
J Am Coll Cardiol. 2000 May;35(6):1599-606
pubmed: 10807466
Chest. 2002 May;121(5):1638-50
pubmed: 12006456
Cureus. 2018 Aug 23;10(8):e3193
pubmed: 30402361
J Am Coll Health. 2003 Jul-Aug;52(1):17-24
pubmed: 14717576
Am J Drug Alcohol Abuse. 2019;45(6):644-663
pubmed: 31603710